Novartis nabs two key approvals for Cosentyx to widen its lead on psoriasis rivals

Novartis ($NVS) has been working hard to snap up additional approvals for Cosentyx before its Big Pharma rivals get their next-gen psoriasis contenders to market. And as of Friday, it's done just that in the U.S., where the FDA approved the med as a treatment for psoriatic arthritis and ankylosing spondylitis. With three approvals under its belt, the med could reach peak sales of between $4 billion and $5 billion, Novartis Pharma's global head of development, Vas Narasimhan, said over the summer. More from FiercePharma

Read more on